Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) EBT Margin (2020 - 2026)

GeneDx Holdings has reported EBT Margin over the past 7 years, most recently at 61.04% for Q1 2026.

  • Quarterly EBT Margin fell 5406.0% to 61.04% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 17.5% through Mar 2026, down 587.0% year-over-year, with the annual reading at 4.94% for FY2025, 1229.0% up from the prior year.
  • EBT Margin was 61.04% for Q1 2026 at GeneDx Holdings, down from 15.07% in the prior quarter.
  • Over five years, EBT Margin peaked at 10.29% in Q2 2025 and troughed at 503.13% in Q4 2022.
  • The 5-year median for EBT Margin is 45.6% (2023), against an average of 96.09%.
  • Year-over-year, EBT Margin crashed -43361bps in 2022 and then skyrocketed 45753bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 503.13% in 2022, then surged by 91bps to 45.6% in 2023, then soared by 112bps to 5.66% in 2024, then crashed by -366bps to 15.07% in 2025, then tumbled by -305bps to 61.04% in 2026.
  • Per Business Quant, the three most recent readings for WGS's EBT Margin are 61.04% (Q1 2026), 15.07% (Q4 2025), and 6.33% (Q3 2025).